Affiliation:
1. Department of Cardiology Hacettepe University Faculty of Medicine Ankara Turkey
Abstract
SUMMARYVerapamil SR (180 mg) plus Trandolapril (2 mg) is a potent antihypertensive combination but the efficacy and safety of this treatment has not been studied fully in hypertensive patients with metabolic disorders. We enrolled 298 patients with mild to moderate hypertension who had at least one of the following disorders: diabetes mellitus, hypercholesterolaemia or mild renal failure. The sitting systolic pressure and diastolic blood pressures were significantly decreased after 12 weeks of treatment. Blood pressure was inadequately controlled in only 24 patients (8.8%). Progressive decreases in blood glucose, total cholesterol, low‐density lipoprotein and triglyceride levels were observed during the study. There was no significant change in blood urea nitrogen, creatinine and transaminase levels (p>0.05). There was a significant decrease in microalbuminuria levels. There was no significant change in glycosylated haemoglobin levels in diabetic patients. Verapamil SR plus trandolapril is an effective drug combination in the treatment of hypertension. It may be used safely in patients with diabetes mellitus, hyperlipidaemia and mild renal failure.
Reference15 articles.
1. Antihypertensive agents, serum lipoproteins and glucose metabolism
2. Pathogenesis and treatment of hypertension associated with diabetes mellitus
3. Combination therapy in hypertension;Messerli FH;J Hum Hypertens,1992
4. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V)
5. Recommendations for human blood pressure determination by sphygmomanometer report of a special task force appointed by the steering committee. American Heart Association;Frohlich ED;Hypertension,1988